


This article was downloaded by: [University of Arizona]

On: 21 January 2013, At: 23:24

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/lncn19>

Strong, Specific, Reversible Binding Ligands for Transfer Rna: Comparison By Fluorescence and Nmr Spectroscopies with Distamycin Binding for a New Structural Class of Ligand

Elena V. Bichenkova^a, Seyed E. Sadat-Ebrahimi^a, Amanda N. Wilton^a, Niamh O'Toole^a, Debora S. Marks^a & Kenneth T. Douglas^a

^a School of Pharmacy and Pharmaceutical Sciences, University of Manchester Manchester, M13 9PL, U.K.

Version of record first published: 22 Aug 2006.

To cite this article: Elena V. Bichenkova , Seyed E. Sadat-Ebrahimi , Amanda N. Wilton , Niamh O'Toole , Debora S. Marks & Kenneth T. Douglas (1998): Strong, Specific, Reversible Binding Ligands for Transfer Rna: Comparison By Fluorescence and Nmr Spectroscopies with Distamycin Binding for a New Structural Class of Ligand, Nucleosides and Nucleotides, 17:9-11, 1651-1665

To link to this article: <http://dx.doi.org/10.1080/07328319808004698>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.tandfonline.com/page/terms-and-conditions>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

**STRONG, SPECIFIC, REVERSIBLE BINDING LIGANDS FOR TRANSFER
RNA: COMPARISON BY FLUORESCENCE AND NMR SPECTROSCOPIES
WITH DISTAMYCIN BINDING FOR A NEW STRUCTURAL CLASS OF
LIGAND**

Elena V. Bichenkova, Seyed E. Sadat-Ebrahimi, Amanda N. Wilton, Niamh O'Toole,
Debora S. Marks and Kenneth T. Douglas*
School of Pharmacy and Pharmaceutical Sciences, University of Manchester
Manchester, M13 9PL, U.K.

ABSTRACT

Binding data are presented for the interaction with brewer's yeast tRNA^{Phe} of a new structural family of ligands, symmetrical bis-benzimidazoles. In addition specific perturbations in chemical shifts were detected by 1-dimensional NMR spectroscopy at 400 MHz for some imino and aromatic methyl protons of tRNA^{Phe} when the tRNA was titrated with distamycin. Competitive displacement of the benzimidazole by added distamycin was followed fluorescence spectroscopy.

INTRODUCTION

RNA is increasingly being recognised as a potential drug target, especially in the HIV field ¹. The accessibility of cellular RNAs to xenobiotics and paucity of RNA repair mechanisms means that RNA may offer a therapeutically relevant target for bleomycin ² in particular, and drug design in general. Understanding the molecular features driving strong, specific binding to RNA is a prerequisite to designing RNA-directed ligands as drug leads ³. *In vitro* selection of RNA sequences can determine preferred RNA sequences/structures for antibiotics, e.g. for neomycin ^{4,5} and tobramycin ⁶, but this approach does not produce new RNA binding structures. The complementary approach is to search for novel RNA ligand structures and binding details for diphenylfurans ⁷ and Rev peptide with RNA have appeared ⁸. Following early studies of netropsin and distamycin binding weakly to RNA

(probably electrostatically to the phosphate backbone) ⁹, classical DNA minor-groove ligands, such as berenil ¹⁰ and benzimidazoles ¹¹, have been found to interact strongly with RNA duplexes. However, the grooves of DNA and RNA differ in many respects. For example, 4'-6-diamidino-2-phenylindole (DAPI) binds to AT stretches of B-DNA in the minor groove but intercalates into AU-RNA ³. In view of the accessibility of cellular RNAs to xenobiotics and the paucity of RNA repair mechanisms it has been recognised that RNA may offer a therapeutically relevant target for bleomycin ² in particular, and drug design in general.

We have chosen transfer RNA as a model system with a well-defined tertiary structure to further our understanding of ligand design and recognition principles for RNA. However, there are relatively few types of reversible ligand so far reported for tRNA. These include metal ions, intercalators, polyamines, soft electrophiles, porphyrins, distamycin/netropsin and Hoechst 33258-type heterocyclics. This list is extended by reagents which cleave tRNA as these also often have a binding/ recognition component to their mechanism of action.

Whilst magnesium ions have long been known to specifically stabilise the tRNA tertiary structure, some metal ions bind and cleave RNA specifically ^{12,13}. Metal complexes, either native ¹⁴⁻¹⁶ or attached to an intercalator ¹⁷, have also been used to effect RNA scission. From X-ray studies of Pb²⁺-induced cleavage of yeast tRNA^{Phe} crystals ⁸, specific metal ion cleavages of tRNA have developed ¹². Self-cleaving RNA molecules (ribozymes) can undergo auto-cleavage at specific sites in the presence of Mn²⁺ ions ¹⁹. However, metal ion effects in such RNA molecules are complex as Mg²⁺ ions (inactive alone) can enhance Mn²⁺-cleavage of RNA under certain conditions ¹³. There has been considerable recent emphasis on lanthanide ions to promote scission ¹². We have also shown that thallous (Tl⁺) and thallic (Tl³⁺) ions react specifically with the 5' U₈ residue of *E.coli* tRNA^{Phe} ²⁰. The Tl⁺ ion has been used as a replacement for K⁺ in studies of aminoacyl-tRNA binding and peptidyl transferase activity of ribosomes ²¹.

Acridine ²² and acridine dyes ^{23,24} bind as intercalators to tRNA.



Soft electrophiles form a specific class of reagents for certain modified bases of tRNA. Based on the observation that organomercurials react specifically with the thiouridine (s⁴U₈) in *E.coli* tRNA ^{25,26} and some years ago we introduced organothallium

(III) compounds **1** as specific, reversible binders for the thiouridine site in *E.coli* tRNA^{20,27}. The mercurials may require tRNA structure to be denatured or labilised for reaction²⁵, but the organothallium compounds act specifically (1:1 stoichiometry) against native tRNA²⁰. Arylthallium (III) binding is reversible to gel filtration, with binding constants in the region of low micromolar. Interest in arylthallium (III) modifiers of proteins and tRNA stemmed from the excellent NMR properties of ²⁰⁵Tl (spin ½, natural abundance 70.48%, chemical shift range of ~ 2000 ppm, 19.2% as sensitive as the ¹H nucleus, Tl-H coupling constants are extremely large). This, along with the potential for two crosslinking sites on ArTl₂ (**1**), led to their evaluation against tRNA^{20,27} and proteins^{28,29}.

Polyamine binding to yeast tRNA^{Phe} has been studied extensively including the use of imino proton resonances³⁰ and ¹⁵N NMR spectroscopy³¹.


Porphyrins, which have been used to monitor RNA helix stacking¹⁵, bind to tRNA³² and NMR studies showed the site occupied to be in the TψC arm near residues T54 and ψ55 for brewer's yeast tRNA^{Phe}³³.

Strong evidence that DNA minor groove binders can bind in the tRNA major (deep) groove is provided by the X-ray diffraction study of this tRNA with netropsin and



distamycin (**2**), which shows specific hydrogen bonds to G51, U52 and G53 and electrostatic interactions with phosphates P61, P62 and P63 in this region³⁴. Pullman then detected this netropsin-binding site on tRNA by theoretical calculations³⁵.

We have now found that Hoechst 33258 and its analogs bind strongly and specifically to tRNA. In the UV-visible absorption spectra of mixtures of tRNA (from brewers' yeast) and trihydroxy-Hoechst (**3**) the $\lambda_{\max}$ value of the ligand shifted from 326nm with increasing tRNA concentration, becoming ~338nm for a 1:1 molar mixture. Spectra were obtained for a series of tRNA : trihydroxy-Hoechst mixtures, varying the molar ratio




of the components but keeping a constant total concentration of the components and the corrected absorbances were plotted against the mole fraction of ligand as a Job plot which showed 1:1 complex formation and tight binding ³⁶. Addition of tRNA to solutions of many Hoechst-type analogs leads to fluorescence quenching of the free ligand's fluorescence ³⁷, used to measure the binding constant for the binding of 3,4-dimethoxy-Hoechst (**4**) in 0.1M sodium phosphate buffer, pH 7.80 to tRNA^{Phe}, which obeyed equation (1) for single-site binding with $K_{\text{dis}} = 14.8 + 0.9 \mu\text{M}$.

$$\text{Fluorescence}(F) = F_{\max} \cdot [\text{tRNA}^{\text{Phe}}] / (K_{\text{dis}} + [\text{tRNA}^{\text{Phe}}]) \quad (1)$$

The molecular environment of these ligands on the RNA is different from that on DNA as the fluorescence of Hoechst 33258 (**5**) is enhanced enormously on binding to the DNA minor groove but strongly quenched by tRNA.

In addition to metal ion-based cleavage, selective tRNA cleavage is effected by the chromophore of the enediyne C-1027 ³⁸ and RNA is specifically and efficiently cleaved by Fe(II):bleomycin ².

We now report the specific binding of a new class of bis-benzimidazole ligand to tRNA, with 2,2'-bis(4-hydroxyphenyl)-6,6'-bis-benzimidazole (**6**) as an example. We also describe 1-dimensional NMR spectroscopic studies of the binding of distamycin (**2**) to yeast tRNA^{Phe}. By using competitive fluorescence assays for ligand **6** in the presence of tRNA and distamycin we were able to further probe the binding site of symmetrical bisbenzimidazolic ligands of tRNA.



MATERIALS AND METHODS

tRNA^{Phe} from brewer's yeast was obtained from Boehringer Mannheim. Distamycin was from Sigma Chemical Co. Stock solutions of tRNA were prepared in 0.1M sodium phosphate buffer pH7.8 for the purposes of this study. Ligand **6** was initially dissolved in dimethyl sulfoxide to make a 10mM stock solution, and then further diluted with phosphate buffer to the required concentration. Distilled water was further purified using a Millipore Milli-Q Water Purification System. Samples for fluorescence studies were filtered through a sterile NalgeneTM 0.2 μ m syringe filter.

Synthesis of 6

To a solution of 3,3'-diaminobenzidine (2.164g, 10mmol) in glacial acetic acid (40ml) was added ethyl 4-hydroxybenzimidate hydrochloride ³⁹ (4.201g, 20mmol), 96% pure) and the mixture stirred over a water-bath under reflux and nitrogen for 4 hours to give a light brown mixture. Acetic acid was removed by rotovap, the residue dissolved in hot water (10ml), a mixture of isopropanol: ammonia (10:1, 2ml) added and the resulting mixture stirred over a water bath under reflux for 1 hour. The precipitate was filtered off

and crystallized from methanol to give 3.52g (84% yield, two crops) of the cream product **6**. δ_{H} [270MHz, d_6 -dmsol], 6.90 (d, 4H, Ar-H, $J = 8.6\text{Hz}$), 7.59 (d, 2H, Ar-H, $J = 8.25\text{Hz}$), 7.68 (d, 2H, Ar-H, $J = 8.6\text{Hz}$), 7.84 (s, 2H, Ar-H), 8.68 (d, 4H, Ar-H, $J = 8.6\text{Hz}$), 10.19 (brs, 2H, Ar-OH). FAB mass spectrum: 421 [(M+H)+2, 8], 420 [(M+H)+1, 32], 419 [(M+H), 100]. Accurate mass measurement: calculated for $\text{C}_{26}\text{H}_{19}\text{N}_4\text{O}_2$, 419.1508; found, 419.1525 (error 4ppm).

UV Spectral Measurements

All UV/Visible spectra were recorded at 25°C using a Peltier-thermostatted cuvette holder in a Cary UV-Visible spectrophotometer, model 1E, using the Cary Base System Software.

Fluorescence Spectral Measurements

Fluorescence emission spectra were recorded using a Hitachi fluorescence spectrophotometer, model F-2000. Derivative **6** was excited at 325nm corresponding to its λ_{max} value, determined by UV/Visible spectrophotometry.

Data Analysis

Data were analysed using the Graft program 3.00 from Erithacus Software Ltd.

NMR Spectroscopy

NMR data were accumulated on a Varian VXR400S 400MHz NMR spectrometer equipped with a Sun 4/110 host computer. A dual (inverse) ^1H (X) probehead was used for proton detection. For each spectrum 30000 transients were acquired at 25°C with 1s recycle delay. Data were collected into 32K data points over a spectral width of 10 KHz giving a final resolution of 0.31 Hz/point. Data were processed using VNMR 4.3 software.

Molecular Graphics

Molecular modelling was carried out using SYBYL 6.3.3A (Tripos Associates).

RESULTS

We attempted to determine the site of binding by NMR line-broadening of specific imino protons of yeast tRNA^{Phe}, along the lines used for porphyrins³³, but were unable to do so for any of several Hoechst analogs tried because of solubility problems. Hence we took an indirect route based on the X-ray study of distamycin and netropsin binding to




Figure 1. Titration of the imino-proton region of yeast tRNA^{Phe} using 1D NMR spectroscopy with increasing mole ratios of distamycin as indicated. The imino protons for A31-ψ39(H3), ψ55(H1) and H1 of G18-ψ55 indicated are based on literature assignments⁴⁰. The buffer composition was: 0.1M NaCl, 0.01M NaH₂PO₄/Na₂HPO₄ (pH 7.0), 0.005M MgCl₂ in H₂O/D₂O mixture (95:5 v/v). In all experiments the tRNA^{Phe} concentration was 0.33 mM (0.2μmol in 0.6ml of buffer). The distamycin concentration was changed gradually from zero to 0.66 mM by stepwise addition of aliquots (4μl x 6) of 10mM stock distamycin solution to the 0.6ml NMR sample.




Figure 2A. Molecular graphics indication of resonances selectively broadened in yeast tRNA^{Phe} by distamycin. Residues in bold are those providing the broadened imino protons shown in Figure 1. The yeast tRNA^{Phe} coordinates were from the Brookhaven database ⁴¹.

tRNA ³⁴. We confirmed this binding mode for distamycin by selective NMR line-broadening of some of the imino resonances for yeast tRNA^{Phe}. Thus Figure 1 shows that residues $\psi 55(\text{H1})$ and $\text{G18}(\text{H1})$ - to- $\psi 55$ are selectively broadened based on these literature assignments of these peaks ⁴⁰. Porphyrins have been found to selectively broaden imino protons located on bases T54 and $\psi 55$, located at the outer edge of the elbow-bend of tRNA ³³. We also found evidence of selective broadening by distamycin of aromatic methyl resonances arising from the RNA and that the three N-CH₃ proton resonances of distamycin are shifted upfield by ~3.8 ppm to 2.75 - 2.95 ppm in their tRNA complex (data not shown).




Figure 2B. Molecular model showing the distamycin site of yeast tRNA^{Phe} using literature coordinates for tRNA⁴¹ and data reported for the tRNA: distamycin complex analyzed by X-ray diffraction data³⁴.

Also a new resonance appeared at 9.6 ppm (shifting to ~ 9.4 ppm during titration) and probably indicates an additional hydrogen bond formed in the complex as it occurs in the imino region. In Figure 2A, we highlight residues G18 and ψ 55 which provide the imino resonances selectively broadened by distamycin: the tRNA structure was built using the SYBYL programme (Tripos[®] Associates) and the reported X-ray coordinates of yeast tRNA^{Phe}⁴¹. These lie at one end of the general binding region reported by X-ray for distamycin³⁴, for which data are not in the Brookhaven Database, but for which we built a model (Figure 2B) using available tRNA coordinates⁴¹ and published data for distamycin³⁴.

To detect whether benzimidazole-based ligands also bound to this site, we formed the 1:1 complex of yeast tRNA^{Phe} with the novel ligand **6** which we have shown by UV




Figure 3. Plot of the change in fluorescence of *bis*-2,2'-bis (4-hydroxyphenyl)-6,6'-bis-benzimidazole (**6**) on addition of yeast tRNA^{Phe}. A sample (2ml) of **6** was excited at 325nm, and aliquots (20 μl) of 10 μM tRNA^{Phe} were added with the fluorescence being recorded after each addition. Both the tRNA^{Phe} and **6** were prepared in 0.1M Tris buffer containing 0.1M NaCl, 0.01M MgCl₂, pH 7.5. Points are experimental : line is theoretical for a single binding site with $K_{\text{diss}} = 0.598 \pm 0.044$ μM.

spectral shifts and Job plots binds to tRNA. The consequent quenching of the native fluorescence of the free ligand on binding to it of tRNA was used to determine the binding isotherm, see Figure 3, from which a dissociation constant for the complex of 0.598 ± 0.044 μM was measured.

Titration of this complex with increasing amounts of distamycin (Figure 4) led to release of free **6**, detected by the increase in fluorescence associated with non-bound **6**, with an apparent K_{diss} from the binding equation for a single-binding site of 9.6 ± 2.2 μM. Whilst conformational effects on tRNA cannot be excluded, the simplest explanation is that both ligands compete for the same or overlapping sites. Ligand **6** represents a new class of nucleic acid-directed ligand with a defined, specific binding site on tRNA.

The molecular structures of these families of ligands and the specific recognition of a particular region of tRNA (the benzimidazoles and distamycin selectively occupy a unique




Figure 4. Fluorescence decrease of a 1:1 complex of yeast tRNA^{Phe} with ligand **6** when distamycin concentration is increased. A solution containing 2ml of 0.1 μM **6** and 60 μl of tRNA^{Phe} (0.291 μM) was excited at 325nm, and 30 μl aliquots of 180 μM distamycin were added, with the fluorescence being recorded after each addition. Both the tRNA^{Phe} and the distamycin were prepared in 0.1M Tris buffer, containing 0.1M NaCl, 0.005M MgCl₂, pH 7.5. Points are experimental : line is theoretical for a single binding site with an apparent dissociation constant of $9.6 \pm 2.2 \mu\text{M}$.

run of 4-5 base-pairs out of approximately 75 bases) provides new lead structures to study the molecular basis of ligand:RNA recognition at an atomic level. The compounds also provide a rare example of stoichiometric ligand recognition by tRNA in a readily reversible equilibrium as opposed to covalent attack.

ACKNOWLEDGEMENTS

We are grateful to the Royal Society/NATO for a Postdoctoral Fellowship and support (EVB) and to the Wellcome Trust for a studentship (DSM). We are also grateful to the BBSRC for the provision of 400MHz NMR instrumentation, to the School of Biological Sciences at the University of Manchester for access to it and to Drs Gareth Morris and Martin Barron for assistance.

REFERENCES

- (1) Mitsuya, H.; Yarchoan, R.; Broder, S. *Science* **1990** *249*, 1533-1543.
- (2) Carter, B. J.; de Vroom, E.; Long, E. C.; van der Marel, G. A.; van Boom, J. H.; Hecht, S. M. *Proc. Nat. Acad. Sci. (U. S. A.)* **1990** *87*, 9373-9377.
- (3) Tanious, F. A.; Veal, J. M.; Buczak, H.; Ratmeyer, L. S.; Wilson, W. D. *Biochemistry* **1992** *31*, 3103-3112.
- (4) Wallis, M. G.; von Ahsen, U.; Schroeder, R.; Famulok, M. *Chemistry and Biology* **1995** *2*, 543-552.
- (5) Famulok, M.; Huttenhofer, A. *Biochemistry* **1996** *35*, 4265-4270.
- (6) Wang, Y.; Rando, R. R. *Chemistry and Biology* **1995** *2*, 281-290.
- (7) Ratmeyer, L.; Zapp, M. L.; Green, M. R.; Vinayak, R.; Kumar, A.; Boykin, D. W.; Wilson, W. D. *Biochemistry* **1996** *35*, 13689-13696.
- (8) Peterson, R. D.; Feigon, J. *J. Mol. Biol.* **1996** *264*, 863-877.
- (9) Zimmer, C.; Reinert, K. E.; Luck, G.; Wahnert, U.; Lober, G.; Thrum, H.J. *Mol. Biol.* **1971** *58*, 329-348.
- (10) Pilch, D. S.; Kirolos, M. A.; Liu, X.; Plum, E.; Breslauer, K. J. *Biochemistry* **1995** *34*, 9962-9976.
- (11) Wilson, W. D.; Ratmeyer, L.; Zhao, M.; Srekowski, L.; Boykin, D. *Biochemistry* **1993** *32*, 4098-4104.

- (12) Ciesiolka, J.; Wrzesinski, J.; Gornicki, P.; Podkowinski, J.; Krzyzosiak, J. *Eur. J. Biochem.* **1989** *186*, 71-77.
- (13) Kazagov, S.; Altman, S. *Proc. Nat. Acad. Sci. (U. S. A.)* **1992** *89*, 7939-7943.
- (14) Chow, C. S.; Barton, J. K. *J. Am. Chem. Soc.* **1990** *112*, 2839-2841.
- (15) Celander, D. W.; Nussbaum, J. M. *Biochemistry* **1996** *35*, 12061-12069.
- (16) Murakawa, G. J.; Chen, C. B.; Kuwabara, M. D.; Nierlich, D. P.; Sigman, D. S. *Nucl. Acids Res.* **1989** *17*, 5361-5375.
- (17) Kean, J. M.; White, S. A.; Draper, D. E. *Biochemistry* **1985** *24*, 5062-5070.
- (18) Brown, R. S.; Hingerty, B. E.; Dewan, J. C.; Klug, A. *Nature (London)* **1983** *303*, 543-545.
- (19) Dange, V.; Van Atta, R. B.; Hecht, S. M. *Science* **1990** *248*, 585-588.
- (20) Baindur, S. R.; Douglas, K. T. *Biochim. Biophys. Acta* **1987** *923*, 66-73.
- (21) Hutlin, T.; Naslund, P. H. *Chem.-Biol. Interact.* **1974** *8*, 315-328.
- (22) Borisova, O. F.; Potapov, A. P.; Surovaya, A. N.; Trubitsin, S. N.; Vol'kenshtein, M. V. *Mol. Biol. (USA)* **1974** *7*, 411-417.
- (23) Surovaya, A. N.; Trubitsin, S. N. *Mol. Biol. (USA)* **1974** *7*, 403-410.
- (24) Urbanke, C.; Romer, R.; Maass, G. *Eur. J. Biochem.* **1973** *33*, 511-516.
- (25) Heitner, H. I.; Lippard, S. J.; Sunshine, H. R. *J. Am. Chem. Soc.* **1972** *94*, 8936-8937.

- (26) Pal, B. C.; Shugart, L. R.; Sham, K. R.; Stulberg, M. P. *Arch. Biochem. Biophys.* **1972** *150*, 86-90.
- (27) Baindur, S. R.; Douglas, K. T. *J. Chem. Soc. Chem. Commun.* **1985**, 1398-1399.
- (28) Bunni, M. A.; Douglas, K. T. *Biochem. J.* **1984** *217*, 383-390.
- (29) Bunni, M. A.; Baindur, S. R.; Douglas, K. T.; Drake, A. F. *Biochim. Biophys. Acta* **1987** *923*, 421-430.
- (30) Heerschap, A.; Walters, J. A.; Hilbers, C. W. *Nucl. Acids Res.* **1986** *14*, 983-998.
- (31) Frydman, L.; Rossamando, P. C.; Frydman, V.; Fernandez, C. O.; Frydman, B.; Samejima, K. *Proc. Natl. Acad. Sci. USA* **1992** *89*, 9186-9190.
- (32) Foster, N.; Singhal, A. K.; Smith, M. W.; Narcos, N. G.; Schray, K. J. *Biochim. Biophys. Acta* **1988** *950*, 118-131.
- (33) Birdsall, W. J.; Anderson, Jr.; Foster, N. *Biochim. Biophys. Acta* **1989** *1007*, 176-183.
- (34) Rubin, J.; Sundaralingam, M. *J. Biomol. Struct. Dynamics* **1984** *2*, 165-174.
- (35) Zakrzewska, K.; Pullman, B. *J. Biomol. Struct. Dyn.* **1984** *2*, 737-743.
- (36) Sadat-Ebrahimi, S. E.; Wilton, A. N.; Douglas, K. T. *J. Chem. Soc. Chem. Commun.* **1997**, 385-386.
- (37) Sadat-Ebrahimi, S. E.; Wilton, A. N.; Douglas, K. T. *J. Biomol. Struct. Dyn.* **1997** *14*, 923-924.
- (38) Totsuka, R.; Aizawa, Y.; Uesugi, M.; Okuno, Y.; Matsumoto, T.; Sugiura, Y. *Biochem. Biophys. Res. Commun.* **1995** *208*, 168-173.

- (39) Ebrahimi, S. E. S.; Bibby, M. C.; Fox, K. R.; Douglas, K. T. *Anti-Cancer Drug Design* **1995** *10*, 463-479.
- (40) Heerschap, A.; Walters, J. A. L. I.; Hilbers, C. W. *Nucl. Acids Res.* **1986** *14*, 983-998.
- (41) Westhof, E.; Sundaralingam, M. *Biochemistry* **1986** *25*, 4868-4876.